In addition, studies have illustrated that CD4+ T‐cell ICOS expression increases in peripheral blood and tumor tissues of patients treated with anti‐CTLA4 for bladder cancer,54 breast cancer,55 and non‐small cell lung cancer.56 This evidence concerns the gene CD4 and breast carcinoma.